Find Academic Supervisors

John Oakey is a Professor and Graduate Coordinator in the Department of Chemical and Biomedical Engineering at the University of Wyoming, with additional affiliations to the INBRE Program, Molecular and Cellular Life Sciences Program, and Materials Science and Engineering Program. Education Postdoctoral Fellow, Center for Engineering in Medicine, Massachusetts General Hospital & Harvard Medical School (2007–2010) Ph.D. Chemical Engineering, Colorado School of Mines (2003) M.S. Chemical Engineering, Colorado School of Mines (1999) B.S. Chemical Engineering, Penn State University (1997) Research Interests Oakey’s laboratory integrates fluid dynamics, colloidal science and materials science to understand how biological systems behave under flow, on surfaces and within complex 3-D geometries. A unifying theme is the use of microfabrication and microfluidics to create new diagnostic, prognostic and therapeutic platforms. Current thrusts include: Heterogeneous biomaterials: self-assembled particulate tissue scaffolds whose mechanical and transport properties can be temporally programmed. Inertial microfluidics: exploiting lift forces for membrane-free particle sorting, enrichment and diagnostics. Multi-temporal analysis by flow cytometry: development of closed-loop, high-throughput microfluidic cytometers for longitudinal single-cell studies. Publication Trends From 2025 back to 2010, Oakey’s articles reveal a consistent trajectory that marries fundamental physics (microtubule mechanics, inertial focusing) with translational applications (cell encapsulation, tissue scaffolds, drug delivery). Recent work (2023-2025) increasingly targets injectable granular hydrogels, single-cell therapeutic delivery and sustainable carbon-sequestering living materials, demonstrating an evolution from microscale transport phenomena to macroscopic biomedical and environmental impact. Scientific Awards No named awards are listed in the supplied text. Advising & Coordination Roles As Graduate Coordinator for the Department of Chemical and Biomedical Engineering, Professor Oakey oversees graduate program development and student mentoring. While no individual students are named, his role implies active supervision of M.S. and Ph.D. advisees in chemical and biomedical engineering. Laboratory & Teams The Oakey Research Group operates from the Energy and Environmental Research Building (EERB 435A) at the University of Wyoming. The lab enjoys R1-level research infrastructure and collaborates broadly with the Wyoming INBRE network, the Molecular and Cellular Life Sciences Program, and the Materials Science and Engineering Program.

• Microfluidics
• Microscale transport phenomena
• Tissue engineering and regenerative medicine
• +4 more

Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.

• Antibody-Drug Conjugates
• Cancer Chemotherapy
• Medicinal Chemistry
• +3 more

Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.

• HIV-related cardiometabolic complications
• Antiretroviral therapy optimization
• Pediatric infectious diseases
• +7 more

Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.

• Biomaterials
• Regenerative Engineering
• Therapeutic Delivery
• +3 more

Bradley D. Olsen is a full professor in the Department of Chemical Engineering at the Massachusetts Institute of Technology (MIT), where he leads research at the intersection of polymer science, soft matter physics, and bioengineering. His work focuses on designing materials for critical applications in biotechnology, hemostasis, and sustainable polymer development while advancing fundamental understanding of polymer network mechanics and self-assembly. Education: Ph.D. in Chemical Engineering, University of California Berkeley (2007) S.B. in Chemical Engineering, Massachusetts Institute of Technology (2003) Olsen's research spans protein-based materials, block copolymer phase behavior, and mechanochemical hydrogels. He has pioneered methods for quantifying polymer network topology, developing hemostatic nanoparticles, and creating bio-inspired materials for selective biomolecular transport and medical applications. His recent publications emphasize data-driven approaches to polymer characterization and educational outreach in materials science. Scientific Awards: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters Young Investigator Award (2021) MIT Committed to Caring Honor (2019) AIChE Owens Corning Early Career Award (2019) APS Dillon Medal (2018) Kavli Emerging Leader in Chemistry (2017) ACS Polymer Division Fellow (2016) Camille Dreyfus-Teacher Scholar (2015) Alfred P. Sloan Research Fellow (2014) NSF Career Grant (2013) NIH Postdoctoral Fellowship (2008-2009) Hertz Fellow (2003-2007) Barry M. Goldwater Scholarship (2002) Olsen has received significant grant support including NSF Career (2013) and AFOSR (2012) awards. His teaching activities include innovative international outreach like the 2025 soccer-themed science camp in Brazil. The Olsen Group at MIT explores advanced materials with applications ranging from trauma care to sustainable polymers.

• Polymer Science
• Materials Engineering
• Soft Condensed Matter Physics
• +4 more

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +5 more

Hyun (Michel) Koo is a Professor at the University of Pennsylvania School of Dental Medicine , with affiliations in the Department of Orthodontics , Division of Community Oral Health , and Division of Pediatric Dentistry . As Co-Founder and Co-Director of the Center for Innovation & Precision Dentistry (CiPD) , he leads interdisciplinary efforts merging bioengineering, nanotechnology, and oral health research. Education : DDS and PhD Research Focus : Biofilms, bacterial-fungal interactions, and nanotechnology for oral disease prevention Leadership : Co-Director of CiPD; key roles in training programs like NIDCR-sponsored R90 and T90/R90 Dr. Koo’s research explores biofilm mechanisms in oral infectious diseases, particularly childhood caries, through engineering methods and microrobotics . His team developed micron-scale robots for automated biofilm eradication and FDA-approved nanoparticles for caries prevention. Collaborations with Penn Engineering, including Dr. Daeyeon Lee and Dr. Kacy Cullen, emphasize translational approaches. The 15 most recent publications highlight his work in nanorobotics , interkingdom biofilms , and precision diagnostics . Articles span 2025–2024 and address topics like adaptive micromotors , biofilm matrix degradation , and single-cell microbial interactions . These emphasize his focus on targeted therapies and biofilm microenvironment engineering . Key Awards : Elected Fellow, American Association for the Advancement of Science (AAAS) IADR Distinguished Scientist Award for innovative dental research Dr. Koo trains next-generation researchers through the CiPD NIDCR T90/R90 Postdoctoral Training Program , mentoring fellows like Smruti Nair (ACE2 Chewing Gum development) and Zhi Ren (K99 awardee). His work intersects with Penn Health-Tech, CT3N , and Penn Institute for Biomedical Informatics , fostering transdisciplinary innovation.

• Biofilms
• Oral Infectious Diseases
• Nanotechnology
• +3 more

Dr. Kai Gong is an Assistant Professor of Civil and Environmental Engineering at Rice University, with affiliations at the Rice Advanced Materials Institute and Ken Kennedy Institute. His research focuses on sustainable infrastructure materials, environmental sustainability, and materials science. He holds a Ph.D. in Civil & Environmental Engineering and Materials Science from Princeton University, an MEngSci from Monash University (Australia), and dual B.S. degrees from Monash University and Central South University (China). Research Interests: Development of durable, sustainable infrastructure materials Waste encapsulation and conversion to value-added products Carbon mineralization and utilization Advanced characterization techniques (synchrotron/neutron scattering) Data-driven modeling and atomistic simulations Notable Awards: 2023 Le Chatelier Medal (Cement and Concrete Research) 2024 Giatec Award for Best Paper in Sustainability Walbridge Fund Graduate Award (2019) His work integrates computational methods (e.g., molecular dynamics) with experimental techniques to address decarbonization challenges in infrastructure. The Gong Research Group actively seeks motivated researchers for opportunities in sustainable materials innovation.

• Sustainable Infrastructure Materials
• Environmental Sustainability
• Materials Science
• +4 more

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +5 more

Rotem Karni, PhD, is an Associate Professor of Genetics at the Perelman School of Medicine, University of Pennsylvania, Philadelphia. He leads a research lab focused on understanding how alternative RNA splicing contributes to cancer and genetic diseases, with a strong emphasis on translating these findings into RNA-based therapies. Karni's lab develops decoy oligonucleotides, small molecules, and splice-switching technologies to modulate splicing factors and enhance immunotherapy. Education BSc in Biological Chemistry from The Hebrew University of Jerusalem (1997) PhD in Biological Chemistry from The Hebrew University of Jerusalem, Israel (2002) Postdoctoral Fellowship at Cold Spring Harbor Laboratory, NY (2002-2007) Karni's research explores the deregulation of alternative splicing in oncogenesis, particularly how splicing factors like RBFOX2 and S6K1 influence metastasis, DNA repair, and immune checkpoint modulation. His team investigates m6A RNA modifications for stabilizing mutant genes, with applications in Duchenne Muscular Dystrophy and pancreatic cancer. The lab's work is commercialized through biotech companies: SKIP Therapeutics, Andlit Therapeutics, and RNAble. Selected Research Trends RNA mis-splicing and neoantigen generation (2025) Splicing factor inhibition for tumor suppression (2023) Metastatic splicing signatures in pancreatic cancer (2023) Immune checkpoint splicing in cancer immunotherapy (2021) m6A modulation for mRNA stabilization (2023) Advising & Collaborations Karni has mentored numerous PhD and postdoctoral researchers, many of whom now hold leadership roles in academia, biotech, and medical institutions globally. His lab collaborates extensively on projects involving RNA innovation, including partnerships with the Institute for RNA Innovation. Contact Department of Genetics & Institute for RNA Innovation, One uCity Square, Room 4018, Philadelphia, PA 19104 Phone: 215-898-5072 Email: Rotem.Karni@Upenn.edu

• Alternative RNA Splicing
• RNA Biology
• Cancer Therapy
• +4 more

Virgil Percec is the P. Roy Vagelos Professor of Chemistry at the University of Pennsylvania, affiliated with the School of Arts & Sciences and the Department of Chemistry. His research focuses on organic, supramolecular, and macromolecular chemistry, with an emphasis on self-assembly, drug delivery systems, and biomimetic nanosystems. He holds a B.S. and Ph.D. from institutions in Jassy, Romania, and conducted postdoctoral research at the University of Freiburg and the University of Akron. Research Interests: Percec’s work integrates synthetic methods, catalysis, and structural biology to design functional nanosystems. Key areas include hierarchical folding, supramolecular chirality, and synthetic mimics of biological membranes. His lab explores mRNA delivery systems using Janus dendrimers and studies self-organized structures like helical columns and quasicrystals. Recent Articles: His recent publications highlight advancements in mRNA delivery mechanisms, supramolecular architectures, and polymer synthesis innovations. The group’s work often involves interdisciplinary collaborations, bridging chemistry, materials science, and bioengineering. Awards: Percec was elected a Foreign Member of the Academia Europaea (2020) and delivered the inaugural ACS Kavli Lecture (2011). His lab has trained numerous students and postdocs, including Juncheng Lu (Master’s Capstone Award recipient) and Devendra Maurya (SET-LRP research). Labs & Teams: The Percec Research Laboratory at Penn develops cutting-edge biomaterials and supramolecular systems. The group collaborates globally, with projects funded by grants exploring nanotechnology and drug delivery.

• Organic Chemistry
• Supramolecular Chemistry
• Nanotechnology
• +4 more

Andrew D. White is an Associate Professor of Chemical Engineering at the Hajim School of Engineering & Applied Sciences, University of Rochester. He holds a PhD from the University of Washington (2013). His research focuses on automating scientific discovery through AI, particularly leveraging large language models (LLMs) and deep learning techniques in chemistry. His lab develops agents that integrate literature analysis, hypothesis generation, and experimental design to advance fields like molecular dynamics and drug discovery. Education: PhD in Chemical Engineering, University of Washington, 2013 BS/MS (not explicitly stated in text, inferred from career timeline) Research Interests: Large language models for scientific automation Deep learning applications in chemistry and materials science Molecular dynamics simulations Scientific agents and autonomous systems Publications: His work includes groundbreaking studies on closed-loop AI systems for chemistry, federated learning in molecular property prediction, and multi-agent systems for drug discovery. Recent highlights include the Robin system and ChemCrow tools. Awards: Recipient of the NSF Career Award (2018), NIH Outstanding Investigator Award (2020), and the Curtis Teaching Award (2019). He also advises biotech companies and serves on the National Academy of Sciences' Chemical Sciences Roundtable. Grants & Funding: Supported by DOE, NSF (multiple grants including CBET-1751471), NIH (R35GM137966), and LLNL projects. Collaborates with institutions like Argonne National Lab and Qubit Pharmaceuticals. Labs & Teams: Leads the White Lab at Rochester and co-founded FutureHouse, a nonprofit advancing AI-driven scientific discovery. Supervises a multidisciplinary team of PhD students and postdocs in computational chemistry, AI, and biophysics.

• Large language models
• Deep learning in chemistry
• Molecular dynamics
• +5 more

Martin Burke is the May and Ving Lee Professor for Chemical Innovation and Professor of Chemistry at the University of Illinois Urbana-Champaign , with additional appointments in Biochemistry, Biomedical & Translational Sciences, and multiple campus institutes including the Beckman Institute and the Carl R. Woese Institute for Genomic Biology. Education B.S. Johns Hopkins University , 1998 Ph.D. Harvard University , 2003 M.D. Harvard Medical School , 2003 Research Interests Burke’s program centers on molecular prosthetics : the design, synthesis and application of small molecules that replicate or replace missing or dysfunctional proteins. His group pioneered iterative cross-coupling (ICC) using MIDA-protected haloboronic acids to automate the construction of complex natural products and function-oriented small molecules. Current projects target ion-channel replacement in cystic fibrosis, iron-transport restoration in anemia, and non-toxic antifungals that overcome drug resistance. Scientific Awards & Honors National Academy of Medicine (2021) AAAS Fellow (2021) ASCI Member (2021) iCON Award (2019) Mukaiyama Award, Japan (2019) ACS Nobel Laureate Award for Graduate Education (2017) Thieme-IUPAC Prize in Synthetic Organic Chemistry (2014) Elias J. Corey Award (2013) Arthur C. Cope Scholar Award (2011) Research Output & Impact Burke has authored >120 peer-reviewed articles, >30 patents, and his work has been cited >20,000 times. High-impact publications in Nature , Science , and Angewandte Chemie have advanced automated synthesis, molecular prosthetics, and cystic fibrosis therapeutics. Laboratory & Training The Burke Laboratories house a multidisciplinary team of graduate students, post-doctoral researchers, and physician-scientists developing next-generation molecular prosthetics. The group is supported by NIH, NSF, private foundations, and industry partnerships aimed at democratizing molecular innovation.

• Organic Chemistry
• Small-Molecule Synthesis
• Molecular Prosthetics
• +7 more

Karl Griswold is a Professor of Engineering at Dartmouth College's Thayer School of Engineering, where he leads the Griswold Research Group focused on protein engineering and biotherapeutics development. His interdisciplinary work spans chemical, biological, and engineering disciplines to address critical challenges in drug-resistant infections and protein therapeutics. Education: BS in Chemistry from Southwest Texas State University (1995) PhD in Chemistry from the University of Texas at Austin (2005) Research Focus: Professor Griswold's laboratory specializes in protein engineering, directed evolution, and biotherapeutics development , creating novel biomolecules with superior functionality compared to natural proteins. The group develops high-throughput screening methods, protein deimmunization strategies, enhanced expression systems, and antibacterial agents targeting drug-resistant infections. Their work has significant translational potential for treating conditions like MRSA and Pseudomonas aeruginosa infections. Scientific Recognition: Wallace H. Coulter Foundation Early Career Translational Research Award in Biomedical Engineering (2008) NIH Biotechnology Training Grant (2000-2003) Royston M. Roberts - Regents Fellowship, University of Texas (1999) DOW Chemical Foundation Scholar, Texas State University (1991-1995) Senior Fellow, National Academy of Inventors Research Leadership: As co-founder and CEO of Stealth Biologics, Professor Griswold translates academic research into commercial applications. His work has secured NIH funding and Dartmouth Innovations Accelerator support, with research featured in Chemical & Engineering News, Vermont Public Radio, and the New Hampshire Union Leader for developing alternatives to traditional antibiotics. Research Environment: The Griswold Research Group maintains extensive collaborations across disciplines including clinical medicine, immunology, structural biology, and chemical engineering. This interdisciplinary approach prepares trainees for careers at the intersection of multiple scientific fields, with research focusing on Biomolecular Antimicrobial Therapies, Deimmunizing Protein Therapeutics, and Gene Library Construction Technologies.

• Protein engineering
• Directed evolution
• Biotherapeutics
• +2 more

Jessica Williams, PhD is an Assistant Professor in the Department of Neurosciences at the Cleveland Clinic Lerner Research Institute (LRI) with additional faculty appointments at Case Western Reserve University, Kent State University, and Cleveland State University. She serves as the Cleveland Clinic liaison for Kent State University and represents the Clinic on the Executive Council for the Brain Health Institute and the Biomedical Sciences Graduate Program Executive Committee. Education: Postdoctoral Fellowship in Neuroimmunology, Washington University School of Medicine (2017) Ph.D. in Immunology, The Ohio State University (2011) M.S. in Physiology, Purdue University (2006) B.S. in Biology/Chemistry, Lindenwood University (2004) Dr. Williams' research focuses on neuroimmune interactions during multiple sclerosis, particularly examining regional responses of CNS glia to immune stimuli and astrocyte-immune crosstalk. Her lab employs murine MS models, primary human and murine cell analyses, and MS patient lesion assessment to investigate cytokine-mediated neuroprotection and CNS repair mechanisms. Recent work highlights protective astrocyte functions mediated by traditionally deleterious cytokines. Analysis of her 15 most recent publications reveals consistent focus on neuroimmune crosstalk in MS, with increasing emphasis on astrocyte heterogeneity, cytokine signaling (particularly IFNγ), and novel therapeutic targets like immunoproteasomes. Key themes include regional CNS differences in immune responses, glial cell repair mechanisms, and translating basic findings into potential MS therapies. Scientific Awards: Lerner Research Institute Excellence in Education Award (2022) Mentor of the Year Award (2023) Dr. Williams actively mentors the next generation of scientists as evidenced by her CIMER Trained Mentor certification and the graduation of PhD student Brandon Smith. Her research is supported by significant funding from the NIH, National MS Society, W.M. Keck Foundation, Brain Health Research Institute, and Neurological and Vision Impact Area. She regularly serves on study sections for the NIH, National MS Society, and Department of Defense. The Williams Laboratory investigates the interplay between immune and central nervous systems during MS, with current projects examining cytokine-mediated neuroimmune crosstalk for CNS repair and regionally distinct glial responses to inflammation. The lab employs advanced techniques including murine MS models and primary human cell analyses to identify novel therapeutic pathways for MS patients.

• Neuroimmunology
• Multiple Sclerosis
• Astrocyte Biology
• +5 more